Uncategorized Archives - Page 3 of 87 - PsychedelicNewsWire (PNW)

TuesdayDec 19, 2023 9:00 am

DEA Renews Efforts to Ban Psychedelics Despite Backlash in 2022

Last week, the Drug Enforcement Administration (DEA) suggested that DOC and DOI be classified under Schedule I of the Controlled Substances Act in its latest notice. DOC (2,5-dimethoxy-4-chloroamphetamine) and DOI (2,5-dimethoxy-4-iodoamphetamine) are both psychedelic drugs of the amphetamine and phenethylamine chemical classes. In its latest notice, the DEA stated that the medical and scientific basis for suggesting the ban was that these hallucinogens had no known medical value and a high potential for abuse. This is despite the fact that the agency possesses no evidence demonstrating a high abuse potential or directly linking the compounds to severe health events. In…

TuesdayDec 12, 2023 9:00 am

Longevity Movement Looks to Tap Benefits of Psychedelics

America’s longevity movement, a growing community of people committed to reversing aging, is the latest group to take notice of psychedelics. A recent surge of psychedelic-related studies has revealed that hallucinogenic drugs such as LSD, ayahuasca and psilocybin (magic mushrooms) have the potential to treat several mental disorders. These initial studies have found that psychedelics can be especially effective when paired with traditional talk therapy, offering long-term relief against hard-to-treat conditions, including post-traumatic stress disorder (PTSD), eating disorders and treatment-resistant depression, with few side effects and at minimal doses. The findings have been so promising that researchers and mental-health experts…

WednesdayNov 29, 2023 3:07 pm

Four Ways to Boost the Nascent Psychedelics Industry

It is estimated that at least 57 million individuals in America have a mental-health condition. Of this number, roughly 14 million suffer from serious mental issues. Despite these huge numbers, conventional treatments aren’t effective for a significant number of patients, which has prompted many to seek alternative treatments. Psychedelic therapy is one of the popular alternatives as numerous studies have shown that psychedelics could relieve mental health conditions like such as depression, anxiety, substance use disorder and post-traumatic stress disorder. For instance, trials conducted by MAPS have demonstrated effectiveness in the use of MDMA in managing post-traumatic stress disorder. The…

WednesdayNov 01, 2023 11:17 am

VR Widens Possibilities for Psychedelic-Assisted Therapy

Recent advancements in virtual technology may have applications in psychedelic-assisted therapy. Both are relatively new fields that have attracted lots of attention in recent years thanks to their potentially game-changing applications. Psychedelic-assisted therapy has shown it has the potential to offer long-term relief against a variety of mental-health disorders with few if any side effects. Researchers have found that virtual technology may enhance psychedelic-assisted therapy by simulating the visual phenomenology of psychedelic states. With both fields in their infancy, scientists are focusing their efforts on using virtual reality (VR) as a companion to psychedelic-assisted therapy or a potential nondrug alternative.…

FridaySep 29, 2023 3:37 pm

Study Finds Psilocybin Users Less Inclined to Work Overtime

“Quiet quitting” is a phenomenon where employees put in the minimum effort, time and enthusiasm required of them at their jobs and don’t go out of their way to create any extra value for their employers. The trend has picked up a lot of steam in recent years as employees have begun prioritizing a strict work-life balance and finding value in their hobbies and other experiences rather than work. Increased employee demands and stagnating wages coupled with increasing living costs have made many employees question if going the extra mile, whether it's through arriving early, taking part in nonmandatory meetings…

MondaySep 18, 2023 12:11 pm

Study Finds Psychedelic Users Lower Cocaine, Alcohol Intake

Recent research published in the “International Journal of Mental Health and Addiction” has indicated that psychedelic use may result in reduced cocaine intake. The study found that while psychedelic users reported either reducing or completely stopping their intake of cocaine, antidepressants and alcohol, their use of tobacco and cannabis products went up. As psychedelics have been illegal at the state and federal levels for the past several decades, their use has been limited to a small niche community of psychonauts. However, a recent surge in psychedelic research revealed that hallucinogens have the potential to treat a myriad of mental-health disorders…

ThursdaySep 14, 2023 9:00 am

Study Shows Psilocybin Combats Stress by Triggering Rise in Stress Hormone

A new study published in the “ACS Pharmacology & Translational Science” journal has revealed that psychedelics such as psilocybin may combat stress by triggering a temporary increase in stress hormones. The research provides more insight into the potential underlying mechanisms that may allow psychedelics to deliver various mental health benefits. Psilocybin is a psychedelic compound that occurs naturally in certain mushroom species. It is converted into the active form psilocin when ingested and mainly interacts with serotonin receptors in the brain. The traditional “psychedelic experience’” occurs when psilocin interacts with the serotonin 2A receptor subtype and induces feelings of altered…

FridaySep 08, 2023 10:30 am

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’

In July 2023, LSDI launched Twilight, a new sleep aid product The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions LSDI in May 2023 launched its new Mindful product line designed to enhance well-being and promote a mindful approach to life Also in May 2023, the company announced a partnership with non-profit TheraPsil to advance medical psilocybin access and research LSDI announced in April 2023 that its board had approved the repurchase of up to 500,000 shares of its Class…

ThursdaySep 07, 2023 9:30 am

The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction

Lucy Scientific Beats MindMed and Seelos Therapeutics to the Punch Lucy Scientific Discovery (NASDAQ: LSDI) (“Lucy” or the “Company), a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses, just announced the acquisition of the Intellectual Property of High Times, its Licensing Agreements and Royalty Streams in all-stock transaction. This was a brilliant strategic business move. With first movers in the “Mind Science” space like MindMed (NASDAQ: MNMD) and Seelos Therapeutics (NASDAQ: SEEL) realizing than 80% and 40% year-to-date gains respectively, today’s acquisition by Lucy delivers immediate revenue, an expanded product line, a proven and highly influential…

WednesdayJun 21, 2023 1:33 pm

Canadian Study Shows Lower Substance Abuse Cases Among Psychedelics Users

A Canadian research team has published findings indicating that psychedelic use may lower substance abuse rates among users. The study, whose findings were reported in the “International Journal of Mental Health and Addiction,” sought to understand changes in patterns of substance abuse among Canadians after they took psychedelics. As in the United States and Australia, Canada has loosened its psychedelic policies in recent years to finally allow researchers to study their potential benefits and risks. These preliminary studies have revealed that several psychedelics can alleviate the symptoms of mental disorders, such as eating disorders, treatment-resistant depression, anxiety and PTSD. As…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized